Foundation hosts webinar with WHO on mobilising pharmaceutical companies to act on the AMR Political Declaration

Antimicrobial resistance (AMR) is a global challenge that requires active involvement from pharmaceutical companies. As drug-resistant pathogens spread faster than ever, patients worldwide face infections that current treatments can no longer address. Since 2017, the Foundation’s AMR Programme has been monitoring industry efforts, tracking how companies are combating drug resistance and ensuring access to essential products in LMICs. Despite progress, the need for urgent action remains critical. 

In response to the UNGA High-Level Meeting on AMR, which emphasised government responsibilities in the Political Declaration, the Foundation is hosting a live webinar titled 'Mobilising Pharma to act on the AMR Political Declaration.' This event is being held in partnership with WHO during WAAW 2024 and will focus on the roles and responsibilities of pharmaceutical companies in implementing the political declaration on AMR.

About the webinar

The discussion will touch on the specific obligations of pharmaceutical companies in executing the commitments outlined in the political declaration. It will present a clear overview of current industry efforts to combat AMR, including leading examples of best practices, and will identify concrete steps for further advancement. This webinar aims to provide a comprehensive understanding of the current efforts by pharmaceutical companies to combat AMR and to encourage collaborative stakeholder engagement in strengthening and implementing the commitments outlined in the AMR political declaration.

Moderator:

Martijn van Gerven, Research Programme Manager – AMR Programme, Access to Medicine Foundation 

Panelists: 

• Alexandra Cameron, Unit Head at Impact Initiatives and Research Coordination (IRC), WHO  

• Bhakti Chavan, WHO Task Force of AMR Survivors  

• Boumediene Soufi, Global Head Antimicrobial Resistance, Sandoz  

• Maria Larsson Ortino, Senior Global ESG Manager, Legal & General Investment (LGIM)  

• Daniel Shoukimas, Co-Founder & Chief Product Officer, mPharma

Register for the webinar

To join this live event, please follow this link to register your attendance. 

For insights from last year's webinar, watch the video below